Your Good Partner in Biology Research

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Endothelial nitric oxide synthase,eNOS ELISA Kit

Human Endothelial nitric oxide synthase,eNOS ELISA Kit

  • 中文名稱：
    人內(nèi)皮型一氧化氮合成酶(eNOS)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E08322h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3200/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    This Human NOS3 ELISA Kit was designed for the quantitative measurement of Human NOS3 protein in serum, plasma, cell culture supernates, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 1.1 IU/mL-70 IU/mL and the sensitivity is 0.27 IU/mL .

  • 別名：
    cNOS ELISA Kit; Constitutive NOS ELISA Kit; EC NOS ELISA Kit; EC-NOS ELISA Kit; ecNOS ELISA Kit; Endothelial nitric oxidase synthase ELISA Kit; Endothelial nitric oxide synthase ELISA Kit; Endothelial nitric oxide synthase 3 ELISA Kit; Endothelial NOS ELISA Kit; eNOS ELISA Kit; Nitric oxide synthase 3 (endothelial cell) ELISA Kit; Nitric oxide synthase 3 ELISA Kit; Nitric oxide synthase 3 endothelial cell ELISA Kit; Nitric oxide synthase endothelial ELISA Kit; Nitric oxide synthase; endothelial ELISA Kit; NOS 3 ELISA Kit; NOS III ELISA Kit; NOS type III ELISA Kit; NOS3 ELISA Kit; NOS3_HUMAN ELISA Kit; NOSIII ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, cell culture supernates, tissue homogenates
  • 檢測(cè)范圍：
    1.1 IU/mL-70 IU/mL
  • 靈敏度：
    0.27 IU/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Neuroscience
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human eNOS in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　SampleSerum(n=4)
    1:1Average %94
    Range %81-102
    1:2Average %96
    Range %84-115
    1:4Average %108
    Range %90-110
    1:8Average %95
    Range %80-105
  • 回收率：
    The recovery of human eNOS spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9280-105
    EDTA plasma (n=4)9482-100
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    IU/mlOD1OD2AverageCorrected
    702.835 2.697 2.766 2.612
    351.930 1.955 1.943 1.789
    17.51.146 1.159 1.153 0.999
    8.750.673 0.701 0.687 0.533
    4.40.457 0.446 0.452 0.298
    2.20.321 0.326 0.324 0.170
    1.10.243 0.246 0.245 0.091
    00.156 0.152 0.154 　
  • 本試劑盒所含材料：
    • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human eNOS antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
    • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
    • One vial Biotin-labeled eNOS antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
    • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
    • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
    • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
    • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
    • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
    • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
    • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
    • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
    • An instruction manual

    顯示更多

    收起更多

  • 本試劑盒不含材料：
    • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
    • An incubator can provide stable incubation conditions up to 37°C±5°C.
    • Centrifuge
    • Vortex
    • Squirt bottle, manifold dispenser, or automated microplate washer
    • Absorbent paper for blotting the microtiter plate
    • 50-300ul multi-channel micropipette
    • Pipette tips
    • Single-channel micropipette with different ranges
    • 100ml and 500ml graduated cylinders
    • Deionized or distilled water
    • Timer
    • Test tubes for dilution

    顯示更多

    收起更多

  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

引用文獻(xiàn)

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.; Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.
  • 基因功能參考文獻(xiàn)：
    1. NOS3 895(G>T) is significantly associated with recurrence- free survival in patients who received intravesical chemotherapy with pirarubicin after complete transurethral resection. PMID: 30125887
    2. Human gastric cancer tissues with low BUBR1 expression showed no eNOS expression. A decrease in BUBR1 reduced eNOS bioavailability through a pathway other than eNOS phosphorylation. PMID: 30396924
    3. These results suggest that overexpressing or activating eNOS in EOCs increases their survival and enhances their capacity to regulate SMC migration through paracrine effects. PMID: 29343714
    4. This study set out to examine the relationship between renal colic and endothelial nitric oxide synthase gene polymorphisms, but the results show that no relation was found. PMID: 28802544
    5. miR-195 and miR-582 regulated NO release by targeting 3'-UTR of NOS3 post-transcriptionally in endothelial cells PMID: 29948755
    6. binding of IL-5 to IL-5Ralpha receptors enhances angiogenic responses by stimulating the expression of HSP70-1 via the eNOS signaling pathway. PMID: 28317868
    7. that XBP1 splicing can regulate eNOS expression and cellular location, leading to EC migration and therefore contributing to wound healing and angiogenesis PMID: 29352987
    8. Unfavorable genotype of polymorphic variant of candidate gene participating in endothelial dysfunction NOS3 (T786C ) was associated with changes in levels of their active substances in individuals exposed to mercury. PMID: 30351652
    9. 4a/b polymorphism of gene NOS3 in patients with various stages of Pneumoconiosis correlates with early development and unfavorable course of Pneumoconiosis in post-contact period. PMID: 30351692
    10. this study provides that infants with genotype GT eNOS 894G > T have 3.4-fold higher risk of developing of IVH if they are born before 28 + 6 weeks of gestation. PMID: 28211916
    11. Physical interaction between p38 and eNOS was demonstrated by immunoprecipitation, suggesting a novel, NO-independent mechanism for eNOS regulation of TLR4. In correlation, biopsy samples in patients with systemic lupus erythematous showed reduced eNOS expression with associated elevations in TLR4 and p38, suggesting an in vivo link. PMID: 29061842
    12. These results indicated a negative regulatory association between miR24 and NOS3. Downregulation of NOS3 may induce vasospasm following subarachnoid hemorrhage, which may be due to the upregualtion of miR24 in VSMCs. PMID: 29845232
    13. We found a significant relationship between eNOS gene polymorphisms and the congenital heart defects in patients with Down syndrome. Screening for the presence or absence of eNOS polymorphisms may be useful to obtain preliminary data on the risk of congenital heart defects in patients with Down syndrome. PMID: 30204958
    14. Our findings suggest that common genetic polymorphisms in the eNOS gene contribute to risk of erectile dysfunction, presumably by effects on eNOS activity and NO availability. PMID: 29654965
    15. ZYZ-803 stimulated the expression of cystathionine gamma-lyase (CSE) for H2S generation and the activity of endothelial NO synthase (eNOS) for NO production.Blocking CSE and/or eNOS suppressed ZYZ-803-induced H2S and NO production and cardioprotection. PMID: 29288927
    16. Meta-analysis found that eNOS CC genotype was not related to higher susceptibility of migraine compared with TT+ TC genotypes; subgroup analysis showed CC variant increase the risk for migraine compared with TT+ TC genotypes in Caucasian populations, which could not be observed in non-Caucasian populations. There was no significant difference for other genotypes and alleles between migraine patients and healthy controls. PMID: 30200152
    17. This study suggests that T2D patients with different genotypes at CD36, NOS3 and PPARG respond differentially to intervention of omega-3 supplements in blood lipid profiles. PMID: 29703528
    18. Investigated the effect of statins on the expression of sirtuin 1 (SIRT1) and endothelial nitric oxide synthase 3 (eNOS) proteins in young premature myocardial infarction (PMI) patients. Found patients with PMI who were taking statins had a markedly higher level of SIRT1 compared with the controls. The level of eNOS protein was considerably lower in PMI patients compared with the control group. PMID: 29664427
    19. The eNOS-Glu298Asp variant (in mothers and newborns) in association with dyslipidemia (increased cholesterol, LDL and TG levels, and decreased HDL levels) could affect bioavailability of NO and could represent an increased risk for preeclampsia. PMID: 28486825
    20. Increased level of nitric oxide in men with arterial hypeertension did not depend on polymorphic genotypes GG and GT of eNOS gene. PMID: 29658078
    21. The C allele of the eNOS SNP 786 T/C rs2070744 was independently associated with an increased risk for cardiac instability following aneurysmal subarachnoid hemorrhage. PMID: 29079038
    22. A reduction in eNOS and VEGF expression from baseline to the first clinical evaluation may indicate a response to bevacizumab PMID: 28465540
    23. the joint effect of polymorphisms of EDNRB and NOS3 on diabetic retinopathy risk was greater than the individual effect of each polymorphism in the analyzed genetic models PMID: 28817788
    24. polymorphisms in the eNOS "A/A" (homozygous mutant) and ACE "I/D" genotypes might contribute to the increased risk of NSCLC in the South Indian population. PMID: 27328622
    25. The eNOS G894T gene polymorphism was associated with the occurrence and development of coronary heart disease in young people. PMID: 29359785
    26. The frequency of the T allele of eNOS Gene in Type 2 Diabetes was less common than in controls. PMID: 28499789
    27. Our findings suggest that tandem repeat variant within intron 4 of the NOS3 gene is associated with an increased risk of infertility in men diagnosed with idiopathic oligoasthenozoospermia. PMID: 28466478
    28. upregulation of placentaassociated serum exosomal miR155 from patients with preeclampsia may suppress endothelial nitric oxide synthase (eNOS) expression in endothelial cells. PMID: 29328396
    29. eNOS gene SNP rs1808593 genotype may have an important role in predicting the occurrence of pediatric systemic lupus erythematosis and central nervous system complications in pSLE. PMID: 29465350
    30. Findings suggest that NOS3 polymorphisms and physical training are important interacting variables to consider in evaluating redox status, nitric oxide availability and production, and BP control. PMID: 29104725
    31. the eNOS rs1799983 polymorphism and T rs1799983C rs2070744 haplotype might reduce the risk of immunoglobulin A nephropathy in Chinese populations. PMID: 28946141
    32. we reported a novel mechanism for regulation of eNOS uncoupling by low shear stress via autophagy-mediated eNOS phosphorylation, which is implicated in geometrical nature of atherogenesis. PMID: 29466710
    33. NOS3 SNPs are associated with post-exercise hypotension in ethnicity and exercise intensity dependent manner. PMID: 29180482
    34. Acidic pHi reduced NO synthesis and eNOS serine(1177) phosphorylation. Thus, system y(+)L activity is downregulated by an acidic pHi, a phenomenon that may result in reduced NO synthesis in HUVECs. PMID: 29410170
    35. The meta-analysis did not detect any association between eNOS 27VNTR (4b/4a) polymorphism and diabetic microvascular complications susceptibility in Chinese populations. PMID: 29096758
    36. Pitavastatin increases eNOS expression and inhibits of LPS-induced miR-155 expression to prevent HUVEC cell inflammation. PMID: 28664667
    37. 27-bp VNTR polymorphism in intron 4 of eNOS gene polymorphism may be the significant risk factor for systemic lupus erythematosus in south Indian subjects. PMID: 29524578
    38. Our findings provide evidence to support the hypothesis that eNOS -786 T>C polymorphism and the -786C-4a-894G haplotype are associated with the high risk of recurrent pregnancy loss. PMID: 28605668
    39. 6-Gin attenuated the injury of HUVECs induced by HG through the activation of PI3K-AKT-eNOS signal pathway. PMID: 28709132
    40. the two single nucleotide polymorphisms in eNOS gene, G894T and T-786C, are strongly associated with the risk of erectile dysfunction (Meta-Analysis) PMID: 26908069
    41. Extracellular histones disarrange vasoactive mediators release through a COX1-COX2-eNOS interaction in human endothelial cells. PMID: 28244682
    42. rs1799983 NOS3 polymorphism could be associated with hypertension and diastolic blood pressure among Southern Europeans; this association is influenced by dietary fat (saturated fatty acids and monounsaturated fatty acids) and body mass index. PMID: 26994605
    43. The T786C eNOS mutation is common among patients with primary osteonecrosis. PMID: 28877324
    44. Mechanical perturbations sensitize human red blood cell-eNOS to produce nitric oxide. PMID: 27345770
    45. the first work describing the effects of eNOS polymorphisms on different forms of sickle cell disease (SCD), the first enrolling SCD patients of Caucasian origin and the first determining eNOS mRNA levels in peripheral blood from steady-state SCD patients. PMID: 27871907
    46. The development of cholangiocarcinoma (CCA) involves upregulation of eNOS and P-eNOS and their regulators. This may drive angiogenesis and metastasis in CCA. PMID: 27143607
    47. statistically significant correlation didn't exist between serum level of PIN1 and the systolic and diastolic blood pressure, between serum level of eNOS and diastolic blood pressure in the norm tension Alzheimer's disease patients, between serum levels of PIN1, eNOS and systolic blood pressure, and between serum eNOS and systolic and diastolic blood pressure in the patients with hypertension. PMID: 28506742
    48. Study showed the knockdown of VPO1 expression signi fi cantly increased serine1177 phosphorylation of eNOS suggesting that the structural changes and phosphorylation by VPO1 downregulate the expression of eNOS. PMID: 28264790
    49. The -786 T/C polymorphism of NOS3 gene is a susceptibility marker of COPD among Tunisians that correlates with nitric oxide levels and airflow obstruction. PMID: 28526204
    50. Results showed that eNOS and XRCC4 VNTR variants might play a potential role in schizophrenia + nicotine dependence and/or nicotine dependence pathophysiology. PMID: 29050484

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Variation Asp-298 in NOS3 may be associated with susceptibility to coronary spasm.
  • 亞細(xì)胞定位：
    Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Note=Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.
  • 蛋白家族：
    NOS family
  • 組織特異性：
    Platelets, placenta, liver and kidney.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 7876

    OMIM: 163729

    KEGG: hsa:4846

    STRING: 9606.ENSP00000297494

    UniGene: Hs.647092